Compare ONEOK Inc. Common Stock (OKE) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ONEOK Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? ONEOK Inc. Common Stock trades at $91.78 (market cap $58.87B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: ONEOK Inc. Common Stock is far larger — about 5.3× Repligen Corporation Common Stock's market cap, and ONEOK Inc. Common Stock pays a 4.58% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ONEOK Inc. Common Stock for 5 Days and Repligen Corporation Common Stock for 0 Days on average.
| OKE | RGEN | |
|---|---|---|
Market Cap | $58.87B | $11.14B |
Volume | 2,504,054 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $97.51 | $194.57 |
52-Week Low | $64.31 | $102.87 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $91.73B | $11.02B |
Dividend Yield | 4.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONEOK (OKE) trades at $93.38, up 1.48% with a bullish technical outlook and strong fundamental performance. The stock shows solid valuation metrics with P/E of 16.13 and P/S of 1.5, supported by $33.63B revenue and $3.39B net income in 2025. Recent acquisition of Brazos Midstream's assets for $4.425B expands Permian Basin presence, while quarterly dividends remain steady at $1.07 per share.
Outlook remains positive with analyst consensus target of $98.55 (5.5% upside) and no sell ratings. Key risks include integration of recent acquisition and commodity price exposure. Earnings beat expectations in 2 of last 3 quarters, with Q3 2026 results due October 27 providing next catalyst.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ONEOK Inc. Common Stock
ONEOK operates energy infrastructure for natural gas, natural gas liquids, and crude oil. Its assets include pipelines, processing facilities, storage, and related services.
Read more on OKE →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
